Physician profile
Ebrahim Sabbagh
NPI 1811332737
$11,177.39
in general payments reported to CMS, 2019-2025
24 companies · $783 in 2025
The $783 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,763 · 2020: $1,238 · 2021: $541 · 2022: $1,244 · 2023: $3,546 · 2024: $1,063 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,409 · Travel and Lodging: $1,982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,408.73 |
| Travel and Lodging | $1,982.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $6,859.95 | 2019-2025 | Angiojet Ultra 5000a, Ekosonic, Wolverine Coronary Cutting Balloon |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $729.94 | 2020-2025 | Lifevest |
| Abbott Laboratories | $688.06 | 2019-2025 | Amplatzer Amulet |
| Medtronic Vascular, INC. | $536.63 | 2019 | |
| Janssen Pharmaceuticals, INC | $426.12 | 2020-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $406.86 | 2020-2023 | Farxiga, Brilinta |
| Novartis Pharmaceuticals Corporation | $296.49 | 2020-2025 | |
| Abiomed | $175.08 | 2023-2024 | Impella |
| Kestra Medical Technology Services, INC. | $164.39 | 2025 | Assure Wcd |
| Heartflow, INC. | $152.66 | 2023-2025 | Ffrct |
| E.R. Squibb & Sons, L.L.C. | $108.79 | 2021-2025 | Eliquis, Camzyos |
| Cardinal Health 200 LLC | $91.80 | 2019 | |
| Csl Behring | $76.68 | 2022-2025 | Haegarda, Andembry |
| Stryker Corporation | $76.65 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.51 | 2022-2023 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $61.03 | 2022-2023 | |
| Cardiovascular Systems INC. | $51.53 | 2019-2022 | |
| Shockwave Medical, INC | $43.77 | 2023 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave M5+ |
| Amgen INC. | $43.02 | 2021 | |
| Merck Sharp & Dohme LLC | $34.22 | 2022 | |
| Cardiva Medical, INC. | $31.43 | 2025 | Cardiva Vascade 6/7f Vcs |
| Medtronic, INC. | $22.27 | 2025 | Mycarelink |
| Novo Nordisk INC | $16.37 | 2025 | Wegovy |
| Cook Incorporated | $11.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ebrahim Sabbagh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.